Get the Stockscreener App
4.14
2.48%
0.10
After Hours:
4.32
0.18
+4.35%
Sab Biotherapeutics Inc stock is traded at $4.14, with a volume of 60,733.
It is up +2.48% in the last 24 hours and up +58.01% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$4.04
Open:
$4.05
24h Volume:
60,733
Relative Volume:
1.04
Market Cap:
$35.79M
Revenue:
-
Net Income/Loss:
$-42.19M
P/E Ratio:
-6.5714
EPS:
-0.63
Net Cash Flow:
$-25.32M
1W Performance:
+43.25%
1M Performance:
+58.01%
6M Performance:
+2.73%
1Y Performance:
-58.19%
1-Day Range:
$3.7317
$4.3204
1-Week Range:
$2.836
$4.37
52-Week Range:
$2.16
$69.99
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 12.7% - Defense World
Saba Capital Income & Opportunities Fund II (NYSE:SABA) Major Shareholder Sells $37,672.38 in Stock - Defense World
Metric Analysis: Cassava Sciences Inc (SAVA)’s Key Ratios in the Limelight - The Dwinnex
Healthy Upside Potential: Sabre Corp (SABR) - SETE News
Assembly Biosciences keeps Neutral rating after Phase 1a study results - Investing.com
DSMB endorses continuation of Alzheimer's drug trials - Investing.com India
Cassava Sciences Unusual Options Activity For September 23 - Benzinga
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance
Renaissance Technologies LLC Lowers Stock Position in SBA Communications Co. (NASDAQ:SBAC) - Defense World
Sabre Corporation (SABR): Among the Worst AI Stocks To Buy Under $10 - Yahoo Finance
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Morningstar
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer - Defense World
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World
SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World
How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World
SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News
MarketBeat June market recap - SiouxFalls.Business
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow
Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com
CSP Inc insider buys shares worth over $23,000 - Investing.com
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Broker Revenue Forecasts For SAB Biotherapeutics, Inc. (NASDAQ:SABS) Are Surging Higher - Yahoo New Zealand News
Need To Know: The Consensus Just Cut Its SAB Biotherapeutics, Inc. (NASDAQ:SABS) Estimates For 2022 - Yahoo Sport Australia
SAB Bio updates brand to reflect focus on type 1 diabetes therapy By Investing.com - Investing.com Australia
SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook (NASDAQ:SABS) - Seeking Alpha
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):